valine has been researched along with cardiovascular agents in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leary, AC; Lim, PO; MacDonald, TM; McMahon, AD; Shiels, P | 1 |
| Armstrong, PW; Borer, J; Fleming, T; Lipicky, R | 1 |
| BRUNNER, R; HOFMAN, A; SCHLIENTZ, W | 1 |
| Goa, KL; Wellington, K | 1 |
| Laustsen, G; Wimett, L | 1 |
| Alonso, RM; Ferreirós, N; Gonzalez, O; Iriarte, G; Jiménez, RM; Maguregui, MI | 1 |
| Chen, JW; Fang, J; Gao, J; Huang, HQ; Liu, PQ; Tang, FT; Wang, P; Xu, SW; Zhou, SG | 1 |
| Chai, J; Guo, G; Hao, D; Song, F; Zhao, Y | 1 |
| Arts, M; Ben-Shaul, Y; Drose, DR; Gorin, M; Hanganu-Opatz, IL; Kahan, A; Mathar, R; O'Connor, S; Spehr, M; Tsitoura, C; Watznauer, K | 1 |
| Chapman, CA; Sparks, DW | 1 |
2 review(s) available for valine and cardiovascular agents
| Article | Year |
|---|---|
Valsartan: in chronic heart failure.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Agents; Drug Administration Schedule; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2002 |
Drug approval highlights for 2003.
Topics: Acyclovir; Cardiovascular Agents; Cardiovascular Diseases; Dermatologic Agents; Drug Approval; Estrogen Replacement Therapy; Female; Genital Diseases, Female; Genital Diseases, Male; Humans; Immunologic Factors; Male; Mandelic Acids; Skin Diseases; Valacyclovir; Valine; Women's Health | 2004 |
1 trial(s) available for valine and cardiovascular agents
| Article | Year |
|---|---|
Angiotensin II receptor subtype I antagonism and diastolic cardiac filling in man.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Cardiovascular Agents; Cross-Over Studies; Diastole; Double-Blind Method; Echocardiography; Heart Failure; Hemodynamics; Humans; Male; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 1999 |
7 other study(ies) available for valine and cardiovascular agents
| Article | Year |
|---|---|
Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
Topics: Adrenergic beta-Antagonists; Advisory Committees; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black People; Canada; Cardiovascular Agents; Drug Approval; Heart Failure; Humans; Hyperkalemia; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Renal Insufficiency; Spironolactone; Survival Rate; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2001 |
[D-LYSERGYL-L-VALINE METHYL ESTER, A NEW NATURAL ERGOT ALKALOID].
Topics: Cardiovascular Agents; Chemistry, Pharmaceutical; Ergot Alkaloids; Pharmacy; Research; Valine | 1963 |
Validation of a fast liquid chromatography-UV method for the analysis of drugs used in combined cardiovascular therapy in human plasma.
Topics: Cardiovascular Agents; Chlorthalidone; Chromatography, Liquid; Drug Stability; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tetrazoles; Time Factors; Valine; Valsartan | 2009 |
Tanshinone II-A attenuates cardiac fibrosis and modulates collagen metabolism in rats with renovascular hypertension.
Topics: Abietanes; Animals; Blood Pressure; Cardiovascular Agents; Collagen; Drugs, Chinese Herbal; Fibrosis; Gene Expression; Heart; Hypertension, Renovascular; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardium; Phytotherapy; Rats; Rats, Sprague-Dawley; RNA, Messenger; Salvia miltiorrhiza; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2010 |
Effectiveness evaluation of cardiovascular drugs based on CYP2C9 target protein.
Topics: Cardiovascular Agents; Cytochrome P-450 CYP2C9; Fuzzy Logic; Humans; Tetrazoles; Valine; Valsartan | 2015 |
Interdependent Conductances Drive Infraslow Intrinsic Rhythmogenesis in a Subset of Accessory Olfactory Bulb Projection Neurons.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Calcium; Calcium Channel Blockers; Cardiovascular Agents; Excitatory Amino Acid Antagonists; Group II Phospholipases A2; In Vitro Techniques; Mice; Mice, Inbred C57BL; Models, Neurological; Neurons; Olfactory Bulb; Olfactory Pathways; omega-Agatoxin IVA; Periodicity; Pyrimidines; Spider Venoms; Valine | 2016 |
Heterosynaptic modulation of evoked synaptic potentials in layer II of the entorhinal cortex by activation of the parasubiculum.
Topics: Afferent Pathways; Analysis of Variance; Animals; Bicuculline; Cardiovascular Agents; Electric Stimulation; Entorhinal Cortex; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; GABA-A Receptor Antagonists; Hippocampus; Male; Patch-Clamp Techniques; Phosphinic Acids; Pyrimidines; Rats; Rats, Long-Evans; Synapses; Time Factors; Valine | 2016 |